Combining mental rehearsal and vestibular therapy for relapsing‑remitting MS

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized controlled trial will test an 8-week combined program of motor imagery and vestibular rehabilitation against conventional therapy in people with relapsing‑remitting MS. Participants with mild disability (PDDS 0–3), mild cognitive impairment, and vestibular-related balance problems will be recruited and randomized to one of two groups. Outcomes include measures of balance, cognitive performance, physical function, and quality of life collected before and after the intervention. The study aims to determine whether integrating mental-rehearsal techniques with vestibular exercises produces broader or larger benefits than conventional therapy alone.

Why it matters

Who can join: the full rules

inclusion criteria

1. Diagnosis of Multiple Sclerosis (MS) Confirmed using McDonald Criteria
2. Patient diagnosed relapsing-remitting multiple sclerosis (RRMS).
3. Mild MS between 0-3 according to PDDS.
4. Age from (18-45)
5. Mild cognitive impairment
6. Balance impairment (mild to moderate impairment)
7. Vestibular dysfunction Related to MS (dizziness, vertigo , gaze instability ) 8. Native language is Arabic to ensure clear communication during cognitive tasks and exercise instructions

9\. Be able to joined the treatment (motor imagery, vestibular rehabilitaiton )

Exclusion Criteria:

Other neurological disorder, progressive multiple sclerosis Non-MS related vestibular disorders (e.g., BPPV, Meniere's disease) that would interfere with vestibular rehab.

Severe Psychiatric Conditions (schizophrenia, bipolar, etc) Sever balance disorder Sever fatigue Medical instability eg (cardiovascular disease, respiratory, infections, severe uncontrolled diabetes, or severe visual impairments.) Sever cognitive impairment Pregnant Advance disability ( wheelchair , unable to stand ) Use of Vestibular-Suppressing Medications Non - speaker Arabic

Where it's running

• Gehad Salem Mohamed Mohamed Menshawi
  Istanbul, Beykoz/İstanbul, Turkey (Türkiye) Recruiting

Study contacts

• Study coordinator: Gehad Salem menshawi, PT, MSc (Cand.)
• Email: j.menshawi@hotmail.com
• Phone: +201040131964

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• REAL-MS: A Look at Autologous Stem Cell Transplant vs High-Efficacy MS Therapies in Real-World Care

  This study tests how AHSCT compares to high-efficacy MS medicines in adults treated in routine clinical care.

  Recruiting Imperial College London · London and 2 other locations · NCT07899502

• Brain Imaging and Immune Changes During Remibrutinib in Relapsing MS

  This study tests how remibrutinib affects brain inflammation in people with relapsing MS who are also on ocrelizumab.

  Recruiting Washington University School of Medicine · St Louis, Missouri · NCT07758270

• Wearable focal vibration to improve arm and hand function in relapsing-remitting MS

  This pilot will try a home-based wearable focal vibration device on arm muscles to see if it improves arm and hand function in adults with relapsing-remitting multiple sclerosis.

  Recruiting at 2 sites University of Florida · Gainesville, Florida and 1 other locations · NCT07376772

• Home-based functional balance program for people with multiple sclerosis

  This project will test whether a home-based functional balance program helps adults with multiple sclerosis improve physical and cognitive function and daily activities.

  Recruiting University of Illinois Chicago · Chicago, Illinois · NCT07355387

• Monthly blood monitoring of neurofilament light to detect hidden activity in treated relapsing-remitting MS

  This will test whether monthly blood measurements of neurofilament light (pNfL) can find hidden disease activity in people with treated relapsing-remitting MS.

  Recruiting at 4 sites Centre Hospitalier Universitaire de Nīmes · Montpellier and 5 other locations · NCT07292480

• Ublituximab (Briumvi) for early relapsing MS

  This study will test whether giving Ublituximab (Briumvi) about twice a year is safe and changes a blood marker (neurofilament light) in adults with early relapsing MS.

  Recruiting Phase 4 Northwestern University · Chicago, Illinois · NCT07225361

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.